The World Health Organization (WHO) said on Wednesday the only approved vaccine against malaria should be widely given to African children, potentially marking a major advance against a disease that kills hundreds of thousands of people annually.
The majority of people who die from malaria are children under age five.
The recommendation from WHO is for RTS,S — or Mosquirix — a vaccine developed by British drugmaker GlaxoSmithKline (GSK).
Since 2019, 2.3 million doses of Mosquirix have been administered to infants in Ghana, Kenya and Malawi in a large-scale pilot program co-ordinated by WHO.
That program followed a decade of clinical trials in seven African countries.
“This is a vaccine developed in Africa by African scientists and we’re very proud,” said Tedros Adhanom Ghebreyesus, WHO director-general.
“This vaccine is a gift to the world, but its value will be felt most in Africa.”
Vaccine to be used with bednets, spraying: WHO
Malaria is far more deadly than COVID-19 in Africa. It killed 386,000 Africans in 2019, according to a WHO estimate, compared with 212,000 confirmed deaths from COVID-19 in the past 18 months.
WHO says 94 per cent of malaria cases and deaths occur in Africa, a continent of 1.3 billion people. The preventable disease is caused by parasites transmitted to people by the bites of infected mosquitoes. Symptoms include fever, vomiting and fatigue.
The Mosquirix recommendation was jointly announced in Geneva on Wednesday by WHO’s top advisory bodies for malaria and immunization, the Malaria Policy Advisory Group and the Strategic Advisory Group of Experts on Immunisation.
On Wednesday, nearly six years later and two years after the start of the pilots, WHO panels recommended the vaccine be rolled out for children across African nations where malaria is endemic, alongside the other authorized means of preventing malaria such as bednets and spraying.
The vaccine’s effectiveness at preventing severe cases of malaria in children is only around 30 per cent, but it is the only approved vaccine. The European Union’s drugs regulator approved it in 2015, saying its benefits outweighed the risks.
In late 2015, the WHO expert panels called for a pilot program in three to five African countries to inform a future decision about widespread use of the vaccine.
In 2019, the WHO said the fight against malaria had stalled. But on Wednesday, it said that using the vaccine as an additional tool against the disease could save tens of thousands of lives each year.
“This is how we fight malaria, layering imperfect tools on top of each other,” said Ashley Birkett, who leads global malaria vaccine work at Path, a non-profit global health organization that has funded the development of the vaccine with GSK and the three-country pilot.
Another vaccine against malaria, developed by scientists at Britain’s University of Oxford and called R21/Matrix-M, showed up to 77 per cent efficacy in a year-long study involving 450 children in Burkina Faso, researchers said in April, but it is still in the trial stages.
WHO’s decision had personal meaning for Dr. Rose Jalong’o, a vaccinology specialist at the Kenyan health ministry.
“I suffered from malaria as a child and during my internship, and during my clinical years I attended to children in hospital because of severe malaria who needed blood transfusion and unfortunately some of them died.”
“It’s a disease I have grown up with and, seeing all this in my lifetime, it’s an exciting time.”
COVID response shows funding is possible, WHO says
Experts said the challenge now would be mobilizing financing for production and distribution of the vaccine to some of the world’s poorest countries.
A global market study led by WHO this year projected demand for a malaria vaccine would be 50 to 110 million doses per year by 2030 if it is deployed in areas with moderate to high transmission of the disease.
GSK has to date committed to produce 15 million doses of Mosquirix annually, in addition to the 10 million doses donated to the WHO pilot programs, up to 2028 at a cost of production plus a margin of no more than five per cent.
The GAVI vaccine alliance, a global public-private partnership, will consider in December whether and how to finance the malaria vaccination program.
“As we’ve seen from the COVID vaccine, where there is political will, there is funding available to ensure that vaccines are scaled to the level they are needed,” said Kate O’Brien, director of WHO’s Department of Immunization, Vaccines and Biologicals.
A source familiar with planning for the vaccine’s development said the price per dose was not yet set, but would be confirmed after GAVI’s funding decision and once there is a clear sense of demand for the vaccine.
GSK welcomed the WHO recommendation.
“This long-awaited landmark decision can reinvigorate the fight against malaria in the region at a time when progress on malaria control has stalled,” Thomas Breuer, chief global health officer, said in a statement.
GSK shares held steady in New York following the announcement, which came after the close of trading in its London-listed shares.
Credit: Source link